<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><description>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 11 Mar 2021 17:13:24 +0800</pubDate><image><url>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</url><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>进军阿尔兹海默症，恒瑞 1 类新药SHR-1707获批临床，13款抗体药物最新进展曝光！</title><link>https://mp.weixin.qq.com/s/81CZrR7a81MHNnG9w4Dx1A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYEfd9gLosRNKdMLDGXEPyiaZnDaY2BRunZiaXKPuxLbWib6DzSNqnmYQrP3ibvtIUBaJvnDnsCkKOq9g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>多元化的恒瑞]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>首仿！石药集团「尼达尼布」获批上市</title><link>https://mp.weixin.qq.com/s/eNNho9PS7NDwRY7Dxd9ZHw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYEfd9gLosRNKdMLDGXEPyiawBzoZGibt7NXaXSbG6NbjIUwVZmjK1drj09kib0OLfPuQDnEH4Em4WpA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>齐鲁制药 2.2 类新药「孟鲁司特钠口溶膜」首家获批</title><link>https://mp.weixin.qq.com/s/wDAyt-mPco2q30yDbq0RWA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYEfd9gLosRNKdMLDGXEPyiaxw60ECuBGQYmCcJHzmObK3iabfgUDp4xbHiavznS5yqFCTiaHFbibhIzqw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>改良型新药，是规避集采的捷径吗]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>普克鲁胺重症 COVID-19 临床结果发布，降低 92% 死亡风险</title><link>https://mp.weixin.qq.com/s/xnpsmydVgrkbBQwd2Y8aTg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYEfd9gLosRNKdMLDGXEPyiaB6st3Qezw8Ujo4Jm4kQ72yLfuW3bvtQKgalaQyesd34UQPPVv2B8uQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>破局晚期乳腺癌治疗，礼来 CDK4/6 抑制剂「阿贝西利片」在中国上市</title><link>https://mp.weixin.qq.com/s/CNtJfFxAafBTE-1Cqw6mgw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYEfd9gLosRNKdMLDGXEPyia3QdGggp6xrnj9sFlUnP9866E0WicKzibhx1FeMViaIh8vSO92Aia8B2mOA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>欢迎免费]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>2021 DIA中国年会初步日程已上线，全新特色专题逐一登场</title><link>https://mp.weixin.qq.com/s/oDspjly9Piov3pptcQDlmg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/xdVx0XiaB89IwRK1ASupyibgGw7ic28YRicMFicbgKc0ZJsoOqNw36DWA2KSpPF61gTl8Fs8wxd44ciaedTibb0aAZaVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2021年5月20-23日，DIA 2021中国年会将再次起航，携手全球药研领域顶尖专家及众多同仁聚首金鸡湖畔，12年历程再看中国药物研发融入全球化，创新再出发！]]></content:encoded><pubDate>Thu, 11 Mar 2021 14:42:40 +0800</pubDate></item><item><title>国内首款埃博霉素类 1 类新药「优替德隆注射液」即将获批</title><link>https://mp.weixin.qq.com/s/dw-zTekkunuPYwSBf14xMQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZbaicWK9Nd8qDGmSX4P5K2iapg9VCoVdm8CH42KqVs0KoUdfTT0uEHbaicich3zxLsnXJxKX4hZYLRqSA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Wed, 10 Mar 2021 10:19:32 +0800</pubDate></item><item><title>刚刚！荣昌生物 1 类新药「泰它西普」正式获 NMPA 批准</title><link>https://mp.weixin.qq.com/s/0PGNOwWVwT3usDsl8DSImA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZbaicWK9Nd8qDGmSX4P5K2iapoqu5CyibIc8gxVDCxbicE5UrHoEiczdPTPauaAyOxetBA3IAYwLyiayQpg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Wed, 10 Mar 2021 10:19:32 +0800</pubDate></item><item><title>石药集团获倍而达药业三代 EGFR-TKI 国内独家授权，近期即将报产</title><link>https://mp.weixin.qq.com/s/3wgtFhdwBQA0gFhWyTMnQA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZbaicWK9Nd8qDGmSX4P5K2iapzq4nibRt8e5vma2yDsSJSlJKndnWB0N7qC7GicDiaysLT72lK9NChHYcg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>首次股权认购 2 亿元]]></content:encoded><pubDate>Wed, 10 Mar 2021 10:19:32 +0800</pubDate></item><item><title>2021 年 2 月 CDE 药品审评报告</title><link>https://mp.weixin.qq.com/s/bnDJaoyITYpaBGSNwbQ2zA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZZWn5CVvRLQ6Js1B5EYTqvu2KAictyeL6P5KTIwgqcn5EuKficwP8RpSUJ04cmvY40phaIIOzau0ZzA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>丁香园 Insight 数据库]]></content:encoded><pubDate>Tue, 09 Mar 2021 18:28:02 +0800</pubDate></item><item><title>继阿斯利康之后，罗氏 PD-L1 撤回了膀胱癌适应症</title><link>https://mp.weixin.qq.com/s/d8ZGuyoLzLyp7OlGu-4KNA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZa0olysdu2fMUQaB7joHPicgs1kpGKicurT56LzjfLJPB1BDDtxkmTrgfJENa44l5SxgYurjHFNeNBw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Tue, 09 Mar 2021 18:28:02 +0800</pubDate></item><item><title>海正药业高级副总裁徐晓艳辞职</title><link>https://mp.weixin.qq.com/s/L0c1Wg8c5HoQ59NIAABWQQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZa0olysdu2fMUQaB7joHPicgWuf2DibZ8BILzYuwGxiacpMGZ1AjdKre2hAPKYZX6SXytZDAmLReC1wA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药企高管离职季]]></content:encoded><pubDate>Tue, 09 Mar 2021 18:28:02 +0800</pubDate></item><item><title>境外已上市境内未上市化药药学研究技术要求（试行）来了</title><link>https://mp.weixin.qq.com/s/OmJ5CNRw9rDA7WmBFxqMhw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZa0olysdu2fMUQaB7joHPicgexXSoI2L06xceicpz2vLKD7jnOuWym1t6PGSYWREeFsYQ42lHS3KMyg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>附全文下载]]></content:encoded><pubDate>Tue, 09 Mar 2021 18:28:02 +0800</pubDate></item><item><title>符合第 5 批集采品种已达 86 个，胰岛素或启动专项采购！(附 Excel 下载)</title><link>https://mp.weixin.qq.com/s/7tTcBzw_mQQy__YhLBC4Zw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZY9ho3cpXQibatNR4F4EJTcJ6DRvmyzRkb5kgNScWkicR4KwibMLoEfuOSDHwfwEBcTx2lF3Sxh9icp9A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>丁香园 Insight 数据库]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:29:31 +0800</pubDate></item><item><title>首仿！正大天晴「仑伐替尼」即将获批</title><link>https://mp.weixin.qq.com/s/qm1eVPbDv71e8vyFKJbrNg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZY9ho3cpXQibatNR4F4EJTcJiaYt8Ig4mV8aeHwItLsE0laQL5Vic5xMOfhjFxN8djO3GeW4QktcFuXQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:29:31 +0800</pubDate></item><item><title>针对二/三线 NSCLC，百济神州 PD-1 第 6 个适应症报上市！</title><link>https://mp.weixin.qq.com/s/Ve_Ew7b3Cyu0pwGNr0mpGw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZY9ho3cpXQibatNR4F4EJTcJp13tcEpVsRSXPqyRXCLdvpBR4sboSY3F7DVwJPelPF3bZ83WSv8kgQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Insight数据库]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:29:31 +0800</pubDate></item><item><title>终版议程大公开|IDC2021化学创新药研发与分析论坛报名通道即将关闭</title><link>https://mp.weixin.qq.com/s/tu1FdxdlSS-kWWkcZTotdA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/9NKpZFWnL9e7j3WVRRmenLHHLFqK9Bial3SS4sjCaic2ROpSjcicNOictR1QcNnevQicJEGq2oJsIH5waNdwIAHdLKg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>终版议程大公开|IDC2021化学创新药研发与分析论坛报名通道即将关闭]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:29:31 +0800</pubDate></item><item><title>都是免疫治疗，PD-1 和 PD-L1 抑制剂到底有什么区别？</title><link>https://mp.weixin.qq.com/s/-89LWS4Dm4XTQFV-G755Bg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYB6wZEkfNw28uMpzSWHEYgbg3JcY8f8AFTmke5Jwzc4PgCJGtIicYdEMzib0NGUtlr5qgYEGmuYWlA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文梳理PD-1/PD-L1抑制剂作用机制、疗效和不良事件差异]]></content:encoded><pubDate>Fri, 05 Mar 2021 18:24:15 +0800</pubDate></item></channel></rss>